Defence Therapeutics Inc. develops a biological drug enhancer platform aimed at improving the efficacy and safety of various pharmaceuticals. The company faces significant concerns, including a low financial health score of 27/100 and a negative return on assets of -40.3%, indicating operational inefficiencies. Additionally, a current ratio of 0.84 suggests potential liquidity issues. While the biotechnology sector holds promise, the company's financial metrics raise red flags that investors should consider.
Loading financial metrics...
Company is burning $777K per quarter with $2.1M in cash. Approximately 2.7 quarters of runway at current burn rate.
Company posted a loss of $-3.7M over the last year, representing Infinity% of revenue.
Strong balance sheet with net cash position provides cushion for growth investments.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q1 (March 31, 2025)